Objectives: The increasing prevalence of mutations in HIV-1 reverse transcriptase (RT) that confer resistance to existing NRTIs and NNRTIs underscores the need to develop RT inhibitors with novel mode-of-inhibition and distinct resistance profiles.
Introduction
HIV-1 reverse transcriptase (RT) plays an essential role in the viral life cycle by converting single-strand viral RNA into double-strand viral DNA via both polymerase and RNase H activities. Thus, identification of RT inhibitors has been one of the primary therapeutic strategies for developing antiviral agents. 1 RT inhibitors are critical components of HAART. There are two classes of HIV-1 RT inhibitors, targeting either the active site or a nearby hydrophobic site of the RT. One class is the NRTIs, which bind to the active site, and the other class is the allosteric NNRTIs, which bind to an inducible pocket 10 Å away from the polymerase active site. 2, 3 Most NRTIs are base analogues and act as chain terminators of DNA polymerization catalysed by RT due to the lack of a 3 0 hydroxyl group for chain extension. Recently, a nucleoside monophosphonate scaffold, a-carboxy nucleoside phosphonate (a-CNP), was identified as a novel RT active-site inhibitor. a-CNP is a mimic of dNTP binding to RT through a carboxylate oxygen. 4 In addition, a new NNRTI, doravirine, was shown to be able to suppress prevalent NNRTIassociated mutants in vitro. 5 Steady-state kinetic studies showed that NNRTIs are noncompetitive with respect to the binding of dNTP and oligonucleotides, [6] [7] [8] [9] indicating that NRTIs and NNRTIs can simultaneously occupy their respective sites. Moreover, cross-talk occurs between the residues in the active site and in the NNRTI binding pocket (NNRTIBP) since the susceptibility of virus containing a thymidine analogue mutation to zidovudine is enhanced if the mutant also carries the NNRTI-associated mutation (K103N). 10 The inhibition of RT by NNRTIs is manifested through a remote effect on the chemical step of polymerization. 11 At the molecular level, transient kinetic studies have shown that NNRTIs impact the rate-limiting step V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
of the incorporation process, making the chemical addition step the slowest step. 12, 13 The nature of this cross-talk between the two binding sites suggests that it may be beneficial to design bifunctional inhibitors to target both sites simultaneously by connecting NRTI and NNRTI moieties together. This strategy may have the benefit of potential synergistic effects from the combination of two inhibitory activities within one molecule. Furthermore, this type of compound can exert additional specificity against the HIV-1 virus, with two moieties targeting two RT binding sites simultaneously, which may improve the safety profile due to elevated specificity versus HIV-1.
As a result, significant efforts have been made in the pursuit of a bifunctional inhibitor of HIV-1 RT. Bifunctional inhibitors targeting other enzyme systems were successfully developed by the combination of FK506 (tacrolimus) binding protein (FKBP) with stromelysin. 14, 15 Two approaches have been taken in the design of RT bifunctional inhibitors. One is to employ a cleavable linker to join the two drugs (an NRTI and an NNRTI), whereby both drugs can be released into the cytoplasm once the bifunctional compound enters the cells. [16] [17] [18] [19] [20] [21] The other is to utilize a non-cleavable linker to connect an NRTI molecule with an NNRTI molecule, whereby the molecule can bind to both sites simultaneously, providing synergistic inhibitory effects. 22 The first approach does not offer the advantages described above because the bifunctional inhibitors behave as two individual molecules once inside the cells. As a result, major efforts were focused on the latter approach in the development of bifunctional inhibitors. For example, 2 0 ,3 0 -dideoxydidehydrothymidine (d4T) was connected with different NNRTI molecules, such as the phenethylthiazolyl (PETT) derivative HI-236 23 and tetrahydroimidazobenzo diazepinone (TIBO), 24 using poly(ethyleneglycol) (PEG) as a linker. In addition, a polymethylene alkyl linker (ALK) was employed to connect thymidine with a TMC derivative (a diarylpyrimidine NNRTI). These derivatives were able to achieve antiviral activity at low nanomolar concentration against RT. 25 Moreover, this inhibitor demonstrated 4.3-fold and 4300-fold enhancement of inhibition relative to the parent TMC derivative and d4T, respectively. These studies serve as a proof of concept for the development and optimization of bifunctional RT inhibitors. However, molecules designed in this way may still possess similar resistance profiles to both original NRTIs and NNRTIs. Here we describe the identification and characterization of novel bifunctional RT inhibitors in which the molecules do not contain a linker and nucleoside-like moiety. The X-ray structure of the RT/ inhibitor complex shows that the bifunctional molecule occupies both the NRTI binding site and the NNRTI binding site with significant interactions with primer grip residues W229 and L234.
Materials and methods

Materials
B-PER buffer and centrifuge columns were from Pierce Biotechnology, Inc. (Rockford, IL, USA). BL21 CodonPlus (DE3)-RIL competent cells were from Stratagene (Cedar Creek, TX, USA). LB-Amp Agar Plates, 1X LB broth, glycerol stock and ampicillin were from Fisher Scientific (Waltham, MA, USA). Hen egg-white lysozyme (2 mg/mL) and 1 M IPTG were from Sigma-Aldrich (St Louis, MO, USA). DNase I and complete EDTA-free tablets were from Roche (Branchburg, NJ, USA). Whatman DE52 resin and streptavidin plus ultralink resin were from Promega (Madison, WI, USA). Amicon Ultra-15 (30 kDa MW, 50 mL tube) was from Millipore (Billerica, MA, USA). YSi scintillation proximity assay (SPA) beads were from GE Healthcare (Port Washington, NY, USA). The Colloidal Blue Staining Kit was from Invitrogen (Carlsbad, CA, USA).
Methods
Generation of HIV-1/2 chimeric RT plasmid
The chimeric RT with the replacement of residues in the HIV-1 NNRTI binding site with corresponding residues in HIV-2 RT (K101A, V106A, E138A, V179I, Y181I, Y188L, G190A, E224D, F227Y and H235W) was created by the sitedirected mutagenesis method via gene synthesis and subcloning into plasmid pTD101, which was derived from pETduet-1 and contained HIV-1 protease cDNA inserted into the first multiple cloning site (mcs) without tags and with HIV-1 RT cDNA (NL4-3 strain) inserted into the second mcs with Mxe intein and AviTag cDNAs at the 3 0 end. The resulting clones were subjected to fluorescence sequencing to verify the presence of the desired mutation(s) and the absence of extraneous mutations. The primers employed for introducing the mutations were as follows (bold type indicates the positions where mutations were made): K101A (forward primer 5 0 -ccattccaagtatcaaca atgcgacgccaggg-3 0 , reverse primer 3
Expression and purification of HIV-1 RT variants
The expression and purification process was similar to that described previously with minor modifications. 26 Briefly, plasmid pTD101, as described above with a specific mutation, was transformed into BL21 CodonPlus (DE3)-RIL competent cells and grown on LB agar plates supplemented with 100 mg/L ampicillin at 37 C. The culture derived from a single colony (10 mL) was used to inoculate 1 L of LB medium supplemented with 100 mg of ampicillin and the resulting culture was grown on a shaker at 25 C at 225 rpm. Induction of protein expression was initiated by addition of 1 mM IPTG when the OD 600 reached 0.6-0.7. Cells were harvested and lysed in B-PER buffer containing 2.5 U/mL DNase I, 20 ng/mL lysozyme and complete EDTA-free protease inhibitor cocktail. The clear lysate after centrifugation was loaded onto a DE52 column equilibrated with Tris buffer (62.5 mM Tris-HCl, 100 mM KCl). The flow-through from the DE52 column was loaded onto a SoftLink avidin affinity column followed by washing with 30 column volumes (CVs) of high salt buffer (500 mM NaCl, 62.5 mM Tris-HCl) and 30 CVs of low-salt buffer (62.5 mM Tris-HCl, 100 mM KCl) sequentially. Untagged RT was eluted by incubating in low-salt buffer containing 50 mM dithiothreitol (DTT) at 4 C to initiate self-cleavage of the Mxe intein. Purified protein was buffer exchanged and concentrated in Amicon Ultra Centrifugal Filter Units with a 30 kDa MW cut-off to reduce the DTT concentration to 1 mM.
HIV-1 RT biochemical assay
The biochemical assay was performed based on the method described previously. 27 Briefly, the heterodimeric nucleic acid substrate used in the HIV-1 RT polymerase reactions was generated by annealing biotinylated DNA primer to a 500 nt RNA template. The HIV-1 RT enzyme (50 pM) was combined with an inhibitor or DMSO (10%) in assay buffer (62.5 mM Tris-HCl, pH 7.8). This mixture was pre-incubated for 30 min at room temperature. The polymerization reaction was initiated by the addition of template/primer Lai et al.
substrate (16.6 nM) and dNTPs (2 lM dCTP, dGTP and dATP and 66.6 nM Ru-dUTP). Reactions were quenched by the addition of EDTA (25 mM) after incubation at 37 C for 90 min. The resulting mixture (50 lL) was transferred to a blocked avidin plate from Meso Scale Discovery. The mixtures were incubated at room temperature for 60 min prior to quantification of the reaction product via an ECL 6000 imager instrument.
SPA-based NNRTI binding site competition assay
A master mix containing HIV-1 RT (5 nM) and the NNRTI binding site probe N-methyl tritiated compound C (Figure 1 ; 78 Ci/mmol, concentration 5 nM) in the assay buffer {50 mM Tris, pH 8.0, 100 mM KCl, 5 mM MgCl 2 , 0.025% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 0.1 mM EGTA} was pre-dispensed into white polypropylene plates. Inhibitors at various concentrations or DMSO (1%) were added to the RT/[ 3 H]-compound C solution and were incubated for 1 h at 4 C followed by the addition of 1/10 volume of YSi SPA beads. The resulting mixture was incubated for another 48 h. Binding of [ 3 H]-compound C to RT was measured by quantifying the emission output using a Perkin Elmer Microbeta TriLux. Non-specific background was determined with reactions lacking RT.
HIV multiple-cycle replication assay
Compounds were tested in HIV-1 multiple-cycle replication assays using genetically defined WT and three laboratory mutant viruses (K103N, Y181C and K103N/Y181C) as described previously. 28, 29 Antiviral activity assays were performed using variants of a laboratory HIV-1 isolate, R8 (NL4-3), and MT4 human T-lymphoid cells in cell culture medium supplemented with 10% normal human serum.
Crystallization
RTs were crystallized by sitting-drop vapour diffusion using a 1:1 mixture of protein, at 50 mg/mL, and a reservoir buffer containing 100 mM sodium cacodylate (pH 6.1) and 800 mM sodium citrate in the absence or presence of Mg 2! (5 mM). Crystals were harvested into the reservoir solution and the compound was added to 0.5 mM concentration and soaked at room temperature. Crystals were transferred into a buffer containing the reservoir solution with the addition of 20% glycerol and vitrified by submersion into liquid nitrogen. Phases were obtained by molecular replacement with an apo structure similar to PDB code 3C6T. The X-ray structure of the RT/inhibitor complex was resolved at 2.6 Å . Data collection, refinement statistics and average B factors are available in Table S1 (available as Supplementary data at JAC Online). In addition, the electron density of compound G and surrounding residues is available in Figure S1 .
Results
Identification of compound A, an RT inhibitor with unique properties
In the process of screening compounds from a Merck compound library to identify novel NNRTIs, the three-ring oxadiazole compound A (Figure 1 ) emerged as a hit of interest during follow-up studies. Despite having modest potency against WT RT (e.g. 8.5+1.7 lM), we found that compound A was more potent against the three most prevalent NNRTI-associated mutant RTs containing K103N, Y181C or K103N/Y181C substitutions compared with WT RT (Figure 2) ; the IC 50s were 2.5+0.2, 0.79+0.14 and 0.75+0.29 lM against K103N, Y181C and K103N/Y181C RTs, respectively. Compound A was 10-fold more potent against Y181C and K103N/Y181C RTs than WT RT, an atypical profile for an NNRTI. Moreover, the potency of compound A was not shifted (IC 50 " 9.1 lM, n " 1) against a common NNRTI-associated triple mutant (G190A/Y181C/K103N) that confers a high level of resistance to currently available NNRTIs such as rilpivirine and efavirenz. 5 These data suggest that compound A may inhibit RT in a novel manner that is distinct from classic NNRTIs.
Characterization of compound A
To better understand the mode of RT inhibition by compound A, we compared the properties of compound A with those of a classic NNRTI (efavirenz) and an active-site inhibitor (foscarnet; Figure 1 ). As described above, compound A may bind to the RT in a different manner from traditional NNRTIs. In addition, with a central oxadiazole ring next to an amide group, compound A may be able to chelate with a metal ion, rendering it able to bind to RT active site. We therefore performed a competition assay to test whether these compounds could displace the radiolabelled compound C bound to RT in the presence or absence of Mg 2! . Compound C is an NNRTI identified in house that displayed an IC 50 of 52 nM, 1.2 lM and 5.5 lM against WT, K103N and Y181C RT, respectively. The , efavirenz retained inhibitory potency, with an IC 50 of 1.3 nM. Compound A, on the other hand, displayed an IC 50 .100 lM under these conditions. Consistent with an active site inhibitor, foscarnet was not able to replace 50% of the radioactivity at concentration .100 lM in the absence of Mg 2! , which is different from the IC 50 of 0.41 lM determined in the presence of Mg 2! (Table 1) . These results suggest that compound A may interact with the RT active site as its binding to RT is Mg 2! dependent. To further investigate whether compound A binds to the NNRTIBP, we generated a variant of RT that lacks a bona fide NNRTIBP; a chimeric RT was generated in which we replaced residues in the HIV-1 NNRTIBP with the corresponding residues from HIV-2 RT, which does not have an NNRTIBP and is thus highly resistant to NNRTIs. The residues that were replaced in HIV-1 RT with the corresponding residues of HIV-2 RT are described in the Materials and methods section. The resulting chimeric HIV-1/2 RT was evaluated for its susceptibility to a series of RT inhibitors with distinct mechanisms of inhibition. As shown in Table 1 , compound A, albeit with lower potency, like the three marketed NNRTIs (efavirenz, nevirapine and etravirine), showed significantly reduced potency against the chimeric RT lacking an NNRTIBP. The active site inhibitor foscarnet, on the other hand, exhibited similar potencies against this chimeric RT and WT HIV-1 RT. In addition, compound B, which is an analogue of foscarnet, showed a similar phenomenon to foscarnet with no potency shift versus WT and chimeric RT, as expected for active site inhibitors. Taken together, these findings indicate that, despite its non-classical activity against NNRTI-resistant mutants, compound A possesses NNRTIlike properties.
Therefore, these results indicate that compound A may be a bifunctional RT inhibitor as evidenced by being unable to bind to chimeric RT lacking NNRTIBP, yet requiring Mg 2! for binding to RT.
Optimization of potential bifunctional RT inhibitors
To explore the structure-activity relationship of compound A and identify more potent inhibitors to enable structural characterization of the binding modes, we synthesized a series of analogues with modifications to the A, B and C rings of compound A (Figure 1 ). We found that even small changes to the A ring had significant detrimental effects on the inhibitory potency and therefore focused our efforts on the modification of the B and C rings. As shown in Table 2 , we were able to improve the potency to low micromolar values by replacing the B-ring 1,3,4-oxadiazole with a diazole moiety. In addition, replacing C-ring 2,3-dihydro-1,4-dioxine with different moieties, such as isoxazole, thiophene or . Experiments were conducted in duplicate. Error bars represent mean + SD. Lai et al.
pyrimidine, improved the potency 15-fold (compound G). As with the parent compound, these analogues did not show decreased potency against RT containing the K103N or Y181C substitution compared with WT RT. The compounds in Table 2 , however, did not exhibit antiviral activity in a cell-based assay, which may be due to limited cell permeability of the compounds. To improve cell permeability, an additional aromatic ring, such as a phenyl, pyridine or pyrimidine group, was added to the C ring. As shown in Table 3 , the potency of the compounds was further improved in a biochemical assay, with IC 50 s as low as 200 nM against WT RT, and there was also no potency shift versus K103N or Y181C RT. More importantly, the series of compounds exhibited antiviral activity with EC 50 in a low micromolar and submicromolar range against WT virus and the K103N mutant.
Structural confirmation of a bifunctional mode of binding
Compounds with improved potency were submitted to crystallization with RT to identify the binding site of this class of compounds. The X-ray structure was successfully obtained for the complex of RT/compound G at 2.6 Å resolution. As shown in Figure 4(a) , compound G simultaneously engages the active site and the NNRTIBP, including the primer grip. Within the NNRTIBP, one face of the A ring of compound G interacts with Y188 and is perpendicular relative to Y181. Moreover, K103 is 24 Å away from the A ring. Common residues associated with NRTI resistance are all far away from compound G. For example, T215, M184, Q151, L74 and K65 are 24, 7.6, 17, 24 and 28 Å distant from the molecule, respectively.
As shown in Figure 4(b) , the molecule appears to be surrounded by a group of hydrophobic residues, for example L228, W229 and K223. More importantly, D186 is in close proximity to the B ring of compound G. The pyrazole ring (B ring) of compound G interacts with D186 directly. It appears that one of the nitrogen atoms in the pyrazole ring is closer to D186 (2.7 Å ) than the other nitrogen atom (3.0 Å ). This close proximity may explain why it does not require Mg 2! for coordinating the interaction between the pyrazole ring in compound G and D186 in RT. Although compound G interacts with the D186 active site residue, the distance between compound G and M184 is 7.6 Å , which suggests the common NRTI-associated mutant M184V substitution may have no impact on the binding of compound G. This contention was supported by the fact that no potency shift was observed when the compound was tested with RT containing the M184V substitution compared with WT RT. The in vitro resistance selection study was not performed due to the modest potency and limited solubility of the compounds. To compare the relative orientations of Y181 and Y188 residues in the presence or absence of an inhibitor, the X-ray structures of apo RT, RT/efavirenz complex and compound G/RT complex were overlaid as shown in Figure 4 (c) I and II. The conformations of both Y188 and Y181 residues in the RT/compound G complex appear to be similar to what was observed in apo RT. In contrast, there are significant alterations of the conformation of the two residues upon binding to efavirenz. As shown in Figure 4 (c) I and II, Y188 and Y181 residues in the RT/efavirenz structure swing 100
(between Ca and Cb) and 90 (between Ca and Cb) relative to their locations in the RT/compound G structure, respectively. The distance between Y188 and Y181 in the complex Bifunctional HIV-1 RT inhibitors JAC of apo/RT or RT/compound G is 5.7 Å , which is similar to the distance (6.5 Å ) between Y188 and Y181 in the complex of RT/efavirenz. In addition, the lack of interactions between Y181 and compound G is consistent with the observation of similar potency of compound G against WT RT and Y181C RT.
On the other face of the A ring, compound G appears to form a p-p stacking interaction with W229 (Figure 4a and b) , which is part of the 'primer grip' in RT, a highly conserved motif responsible for positioning the 3 0 end of the primer for DNA synthesis. Another primer grip residue, L234, contributes to compound G binding. These primer grip contacts, together with a third compound G-interacting residue, Y183, have been shown to be highly conserved, even in treatment-experienced patients. 30 Other significant interactions occur between compound G and residues K223 and L228. These residues are completely conserved in treatment-naive patients and only recently have been labelled accessory mutations and become associated with drug resistance. 31, 32 Interestingly, L228 appears in patients treated with NRTIs alone, while K223 appears in patients treated with both NRTIs and NNRTIs. The C ring of compound G, on the other hand, is mostly exposed to solvent.
Discussion
In this study, we identified and characterized an RT inhibitor with unique properties that are consistent with a bifunctional binding mode. These tricyclic compounds are distinct from traditional bifunctional inhibitors, which are derived by connecting an NRTI molecule with an NNRTI molecule via a linker. Compounds in this new class, on the other hand, are a single entity that possesses two functionalities.
Although the binding of compound A to RT was Mg 2! dependent, there was no coordination of Mg 2! observed in the X-ray structure of RT with compound G even with Mg 2! in the buffer. As a result, compound G may have a different binding mode from compound A, which may be due to the difference in the B ring (oxadiazole versus diazole) of the compounds. Based on the X-ray structures of RT/foscarnet 33 and RT/a-CNP, 4 D186 interacts with 3 0 hydroxyl and a-phosphate oxygens through coordinating with one of the Mg 2! in the RT active site. Given the proximity of the B ring of compound G to D186 (2.7 Å ), D186 may directly interact with the B ring of compound G via hydrogen binding. This contention is consistent with the finding of an in vitro SPA binding assay, which showed that the binding of compound G to RT is Mg 2! independent. In contrast, binding of compound A may be mediated through the presence of Mg 2! in the active site of RT. Interestingly, the C ring of compound G in the complex is mostly exposed to solvent. Close examination of the residues surrounding compound G suggests that compound G is surrounded by a hydrophobic channel containing residues such as K223, L228 and W229. Furthermore, it also suggests that compound G may enter RT through this channel. Thus, once the A ring of compound G approaches Y181, the molecule cannot move any further, rendering the C ring of the molecule exposed to solvent. When compound G entered the binding pocket through the channel, Lai et al.
it formed a p-p stack with Y188 and pushed Y181 to an almost upright position. On the other hand, based on the orientation of Y188 and Y181 residues upon binding to efavirenz, it suggested that efavirenz may enter the binding pocket through the other side of the channel surrounded by residues such as V179, K103, K101 and Y181. Therefore, efavirenz pushes the Y188 residue downward and Y181 away from initial positions after entering the channel. As a result, the orientation of the Y188 and Y181 residues may provide information on how the NNRTIs enter the NNRTIBP. The fact that compound G interacts with highly conserved primer grip residues W229 and L234 and other residues (such as K223 and L228) that have rarely emerged as resistance mutations for RT inhibitors suggests this class of inhibitors may have a high barrier for virus to develop resistance mutations. It has been proposed that the W229 residue should be the prime target amino acid for the rational design of new NNRTIs. 34 One of the potential advantages of the identification of RT inhibitors with a bifunctional binding mode is that the mutant profile of the inhibitors may be distinct from that of NRTIs and NNRTIs. The roles of NRTI-associated mutations are either in discriminating natural dNTP from NRTI-triphosphates or in enhancing the excision rate of incorporated NRTI-monophosphates. 35 Since bifunctional inhibitors of this class do not contain a nucleoside moiety, it is expected that common NRTI-associated mutations would not evolve against this class of inhibitors. Furthermore, it may be harder for the virus to develop resistance mutations to such inhibitors with a bifunctional binding mode because this class of inhibitors may be still capable of binding to RT even if the virus develops a resistance mutation either in the NNRTI or the NRTI binding pocket, as demonstrated by the finding that common NNRTI-associated mutants are susceptible to this class of inhibitors. Therefore, this class of bifunctional compounds represents a novel class of RT inhibitors Bifunctional HIV-1 RT inhibitors JAC that may have a higher genetic barrier for developing resistance mutations.
